In her lecture, Dr Magdalena Trzeciak (Medical University of Gdansk, Poland) advocated combination therapy in AD . Not only can topicals be combined, even novel targeted therapies work better with additional topical treatments.
There are many good reasons for using combinations: they provide additive or synergistic efficacy compared to monotherapy, and as the required dose of individual agents can be reduced, combinations are often more tolerable compared with monotherapy.
Emollients are the cornerstone of AD treatment: they prolong time to flare, reduce the number of flares and the amount of topical corticosteroids (TCS) needed to achieve similar reductions in eczema severity . Their use is also recommended in current guidelines for all AD patients . Emollients restore the impaired barrier function of the epidermis, prevent microbes and irritants from entering the skin, reduce pruritus, and prevent water loss. Even petrolatum has shown not...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Registries – an important research tool in biologics Next Article
Skin toxicity of immune checkpoint inhibitors »
Table of Contents: WCD 2019
Treating Psoriasis in 2019
Atopic Dermatitis – What is New
Dermal Reactions to Systemic Drugs
Lupus Erythematosus Today
Small Molecules – What to Expect
Optimising the Management of Keloids
Malignant Melanoma – Advances in Management
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.